Skip to content

    Recently Viewed


      A male scientist in protective glasses and a Johnson & Johnson lab coat writing on a clear whiteboard
      Home /
      Media Center

      Media Center

      Catch up on the latest Johnson & Johnson news and download the J&J logo and media assets here.

      At Johnson & Johnson our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated and cured, treatments are smarter and less invasive and solutions are personal.

      Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow. We will combine our science and technology with our determination to create a powerful force of care ... and profoundly impact health for humanity.

      Highlighted press releases

      A photo of a Johnson & Johnson signature brick

      Johnson & Johnson Completes Acquisition of Ambrx

      Acquisition strengthens Johnson & Johnson’s commitment to innovation in prostate cancer and deepens pipeline of next-generation antibody drug conjugates and targeted oncologic therapeutics
      Medical technologies
      Two surgeons in full PPE viewing their patient's heart on a monitor in preparation for surgery

      Johnson & Johnson MedTech working with NVIDIA to scale AI for surgery

      Johnson & Johnson MedTech is working with NVIDIA on how its technologies can accelerate secure, real-time analysis of surgical data at the edge Johnson & Johnson MedTech will enable AI-based model development and application deployment, providing a path to scale within its connected digital ecosystem for surgery
      Lede/Promo - Things We Now Know About Pulmonary Arterial Hypertension - Heart

      U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

      OPSYNVI® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to support the implementation of clinical guideline recommendations for early use of combination therapy.1 The comprehensive PAH portfolio at Johnson & Johnson now includes treatments that address all three foundational and guideline-recommended pathways for this rare, progressive disease.2 Approval is based on the results from the pivotal Phase 3 A DUE study, which met its co-primary endpoints, demonstrating significant pulmonary hemodynamic improvement.1

      Contact Global Media Relations

      Journalists please use the following Johnson & Johnson media relations contacts for inquiries.

      We recommend that if you are on deadline—or if it is after business hours—put ON DEADLINE in the subject of your email. It is also helpful if you are as specific as possible with your request.

      Office Telephone: 732-524-1090
      A person using their smartphone to view the Our Credo page on the Johnson & Johnson website

      Media interviews

      Johnson & Johnson has a state-of-the-art production studio available for media interviews. We have an HD-SDI fiber optic cable connection to the All Mobile Video Gateway in Weehawken, New Jersey. From All Mobile Video Gateway, we can be patched to just about anywhere in the United States accessible by fiber optic cable. Our studio can also send our signal to an AMV uplink which allows for international video connections.

      All press releases

      Press Releases


      1,923 Results
      1,923 results

      More information

      Discover J&J

      We are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow.

      Latest news

      Get the latest stories and press releases from Johnson & Johnson.

      Our societal impact

      We seek to provide solutions for some of the world’s most pressing global public health challenges.
      You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.